MenuMenu

Using Stem Cells to Treat Diseases

Cord blood stem cells has been expensively used for therapies as compared to any other sources due to its ready availability and nascent nature delivering better results post therapy. Apart from this the lesser matching required for a therapy using cord blood stem cells as compared to other sources of haemopoetic stem cells makes it the choice of every therapist minimizing the risk associated post therapy. Around 25 years ago, the first human transplant using umbilical cord blood stem cells was performed. At the time, only one disease was treatable using cord blood stem cells. Today, cord blood stem cells can be used in the treatment of nearly 80 diseases and the list continues to develop. Cord blood stem cells have proven track records on treatment of diseases like Thalassemia, Leukemia, Anaemia, Cerebral palsy, Diabetes and various, Blood disorders, Bone marrow syndromes, Cancers, Hemoglobinopathies, Immunodeficiencies, Metabolic disorders. Further more than 300 diseases and conditions are in research progressing towards positive results. New medical technology may well use these cells to rebuild cardiac tissue, repair damage due to stroke or spinal cord injuries and reverse the effects of such diseases as multiple sclerosis or Parkinson’s. While the research is still in its early stages, the possibilities are extremely promising. And, banking your child’s stem cells increases access to any of these technologies in the future

Acute Leukemia

Acute Lymphoblastic Leukemia (ALL)
Acute Myelogenous Leukemia (AML)
Acute Biphenotypic Leukemia
Acute Undifferentiated Leukemia

Chronic Leukemia

Acute Myelofibrosis
Agnogenic Myeloid Metaplasia (myelofibrosis)
Polycythemia Vera
Essential Thrombocythemia

Myelodysplastic Syndromes

Chronic Myelogenous Leukemia (CML)
Chronic Lymphocytic Leukemia (CLL)
Juvenile Chronic Myelogenous Leukemia (JCML)
Juvenile Myelomonocytic Leukemia (JMML)

Phagocyte Disorders

Chediak-Higashi Syndrome
Chronic Granulomatous Disease
Neutrophil Actin Deficiency
Reticular Dysgenesis

Inherited Metabolic Disorders

Mucopolysaccharidoses (MPS)
Confidential For Internal Use Only 17
Hurler’s Syndrome (MPS-IH)
Hunter’s Syndrome (MPS-II)
Scheie Syndrome (MPS-IS)
Sanfilippo Syndrome (MPS-III)
Morquio Syndrome (MPS-IV)
Maroteaux-Lamy Syndrome (MPS-VI)
Sly Syndrome, Beta-Glucuronidase Deficiency (MPS-VII)
Adrenoleukodystrophy
Mucolipidosis II (I-cell Disease)
Krabbe Disease
Gaucher’s Disease
Niemann-Pick Disease
Wolman Disease
Metachromatic Leukodystrophy


Inherited Immune System Disorders

Ataxia-Telangiectasia
Kostmann Syndrome
Leukocyte Adhesion Deficiency
DiGeorge Syndrome
Bare Lymphocyte Syndrome
Omenn’s Syndrome
Severe Combined Immunodeficiency (SCID)
SCID with Adenosine Deaminase Deficiency


Lymphoproliferative Disorders

Non-Hodgkin’s Lymphoma
Hodgkin’s Disease

Inherited Erythrocyte Abnormalities

Beta Thalassemia Major
Sickle Cell Disease

Confidential For Internal Use Only 18

Absence of T & B Cells SCID
Absence of T Cells, Normal B Cell SCID
Common Variable Immunodeficiency
Wiskott-Aldrich Syndrome
X-Linked Lymphoproliferative Disorder

Histiocytic Disorders

Familial-Erythrophagocytic
Histiocytosis-X
Hemophagocytosis

Plasma Cell Disorders

Multiple Myeloma
Plasma Cell Leukemia
Waldenstrom’s Macroglobulinemia

Inherited Platelet Abnormalities

Amegakaryocytosis / Congenital Thrombocytopenia

Other Inherited Disorders

Lesch-Nyhan Syndrome
Cartilage-Hair Hypoplasia
Glanzmann Thrombasthenia
Osteopetrosis

Other Malignancies

Breast Cancer
Wing Sarcoma
Neuroblastoma
Renal Cell Carcinoma


Clinical Trial

Status Sponsor Clinical Trials Gov. Identifier
Hematologic Neoplasms Bone Marrow Failure Syndromes Recruiting participants University of British Columbia, Canada NCT00897260
Traumatic Brain Injury Recruiting participants (Phase II) The University of Texas Health Science Center, Houston, USA NCT01251003
Hematologic Malignancies Recruiting participants (Phase II) Fred Hutchinson Cancer Research Center, USA NCT01175785
Inborn Errors of Metabolism Recruiting participants (Phase I) Duke University, USA NCT00692926
Cerebral Palsy Recruiting participants (Phase II) Duke University, USA NCT01147653
Leukemia Lymphoma Multiple Myeloma Aplastic Anemia Recruiting participants (Phase II) Tufts Medical Center, USA NCT00676806
Spinal cord injuries Recruiting participants (Phase II) China Spinal Cord Injury Network, China NCT01046786
Hematologic Malignancies Recruiting participants (Phase II) Memorial Sloan-Kettering Cancer Center, USA NCT00739141
Hearing Loss Recruiting participants (Phase I) Memorial Hermann Healthcare System, USA NCT01343394
Hypoplastic Left Heart
Syndrome
Recruiting participants (Phase I) Duke University, USA NCT01445041
Type 1 Diabetes Recruiting participants (Phase I) University of Florida, USA NCT00873925
Myelodysplastic Syndrome (MDS)
Severe Aplastic Anemia (SAA)
Recruiting participants (Phase I) National Heart, Lung, and Blood Institute (NHLBI), USA NCT00604201
Address

Cryoviva Biotech Pvt. Ltd.

129, Pace City -1,Sector-37,

Gurugram, Haryana 122001 India

Phone

Tollfree No. : 1800 3002 2796

Helpline No. : (+91) 9582284444

Landline No. : 0124-3341301-305

Email
marketing@cryoviva.in

Reach Us

© 2020 Cryoviva India. All rights reserved